# Anthem Biosciences and the Global GLP-1 Opportunity: A Strategic Move into Generic Semaglutide Manufacturing

> This investment thesis explores Anthem Biosciences' strategic expansion into the high-growth weight loss market through its fully backward-integrated API manufacturing for generic semaglutide. The analysis examines how the company's vertical integration positions it to capture significant market share in both India and international markets as GLP-1 demand surges. Our research evaluates management execution, future growth scenarios, and the competitive landscape of biotechnology manufacturing.

**Companies**: Anthem Bioscienc
**Sectors**: Pharmaceuticals
**Published**: 2026-05-26
**Last Updated**: 2026-05-26
**Source**: https://thesisloop.ai/thesis/d936fb2a-3590-4cf3-85a2-f46549e4c191

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Anthem Bioscienc | 81/100 | 79/100 | 68/100 | 62/100 |

## Anthem Bioscienc (BSE:544449)

**Sector**: Pharmaceuticals | **Industry**: Biotechnology

### Management Credibility

- **[CATALYST] Global Biologics Asset Acquisitions** (NEUTRAL): The company is actively scouting for strategic acquisitions in India and abroad.
  > Secondly, in terms of acquisitions and growth, apart from our organic growth, which is also substantive, we are not averse to looking at acquisitions, both in India and abroad. We are actively searching.
- **[METRIC] CDMO Order Book Growth** (POSITIVE, MET): The company reports that 9MFY26 revenue from Specialty Ingredients (primarily produced at Unit III) is at Rs. 253.5 Cr (INR 2,535 Mn), suggesting the target for the unit is likely to be met or exceeded by year-end. (1 in progress, 2 met across 3 tracked commitments)
  > Our idea would be to push this number to say Rs. 100 Cr - Rs. 150 Cr, by which time we would be supplying. This has been our strategy. We don't like to keep our plants vacant.
- **[PRINCIPLE] Biologics Manufacturing Scale** (POSITIVE, REVISED): Management confirmed the commissioning of the CP7 block (76 kiloliters) in Unit-2 during the last quarter. (3 met, 2 revised across 5 tracked commitments)
  > Commissioning of Fermentation block expected by end of the year
- **[PRINCIPLE] Biosimilar Pipeline Depth** (NEUTRAL): A biosimilar asset currently in progress is expected to impact the P&L in the next financial year. — target: P&L Impact (+3 more commitments)
  > I think, which will hit our P&L next year. Where will we classify it? I think it will go in CRDMO.
- **[PRINCIPLE] CDMO Revenue Diversifies Risk** (NEUTRAL): The company is committed to building one of the most agile, science-led, and future-ready CRDMO platforms in the world as it enters FY27. (+1 more commitment)
  > the long-term target on this is also to deliver about 1.4x - 1.5x on asset turnover. On Rs. 450 Cr capital base, we can generate close to about Rs. 650 Cr of revenues on a long-term basis.
- **[TREND] Contract Biologics Manufacturing Growth** (POSITIVE, MET): The fermentation block at Unit III (NeoAnthem) is still expected to be commissioned by the end of the year. (1 in progress, 2 met across 3 tracked commitments)
  > Fermentation 142 kiloliters, we are adding 40 kiloliters more in NeoAnthem, which should also get done in this calendar year.
- **[TREND] Global Biologics Patent Cliff** (NEUTRAL): The company expects to supply GLP-1 (Semaglutide) to customers in India following patent expirations next year. — target: Supply GLP-1 to Indian customers (+1 more commitment)
  > We expect to be supplying the GLP-1 to our customers in India... next year when the innovator patents expire in India, at that time, during that time, this could be very meaningful addition to your revenue, right? Ajay Bhardwaj: Well, absolutely.
- The company reported EBITDA margins of 44.5% for Q2FY26 and 41.4% for H1FY26, significantly exceeding the 38% target range. (5 exceeded across 5 tracked commitments) (POSITIVE, EXCEEDED)
  > In terms of revenue growth, it will be in the mid-teens around 15% to 16% is what we will be anticipating to end the year with.

### Business Model

- **[METRIC] CDMO Order Book Growth** (POSITIVE, Change: EXPANDING): The CRDMO segment showed significant expansion, delivering INR 452.7 crores in revenue for Q1 FY26, driven by increased demand for commercialized products from 5-6 key clients. (5 expanding)
  > The CRDM business delivered INR452.7 crores revenues out of that... The strong year-on-year growth in this quarter FY26 reflects our CRDM or revenue stream that started ramping up in Q2 of FY25.
- **[METRIC] Biologics COGS per Gram** (POSITIVE, Change: EXPANDING): Backward integration for a key intermediate has been completed, which is expected to protect and improve gross margins in future quarters. (5 expanding)
  > We source the raw material, manufacture the intermediates, manufacture the API and supply to the customer, and we are not reliant on any external source. The backward integration had helped us in terms of improving our material margins.
- **[PRINCIPLE] Analytical Characterization Capability** (NEUTRAL): The company possesses deep technical expertise in complex modalities like peptides, oligonucleotides, and Antibody-Drug Conjugates (ADCs), which are difficult for competitors to replicate.
  > Anthem has capability to do work in all these areas [peptides, oligonucleotides, and ADCs]. Because these are the new modalities and these are new areas of research... Anthem addresses all the problems through, find solutions, technological solutions.
- **[PRINCIPLE] Biologics Manufacturing Scale** (POSITIVE, Change: EXPANDING): Capacity expansion is progressing with 54 kiloliters added in Q1 FY26. Total custom synthesis expansion of 134 kiloliters is on track for completion this calendar year. (5 expanding)
  > Unit 4 is going to be much larger than all the units put together... This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation... We are more or less doubling on custom synthesis and adding 50% more on the fermentation side.
- **[PRINCIPLE] Biosimilar Pipeline Depth** (POSITIVE, Change: EXPANDING): The company is deepening its expertise in high-barrier areas, specifically mentioning 8-9 innovator programs in peptides and the development of a microbial biosimilar for a US customer. (2 expanding)
  > 4 molecules went commercial. So, still at 6 [in Phase-3]... We currently work with innovator peptides, close to about 8-9 programs.
- **[PRINCIPLE] CDMO Revenue Diversifies Risk** (POSITIVE, Change: EXPANDING): Revenue for Specialty Ingredients was INR 87.5 crores. Management noted that while CRDMO is the primary driver, Specialty Ingredients help utilize capacity while client products await approval. (1 stable, 2 expanding across 1 engine)
  > CRDMO 83.9% Q4FY26 Revenue Split... CRDMO business delivered ₹5,128 Mn revenues
- **[TREND] Contract Biologics Manufacturing Growth** (POSITIVE, Change: EXPANDING): The company is expanding its technological moat by commissioning commercial-scale facilities for new modalities like ADCs (Antibody-Drug Conjugates) and Peptides. (2 expanding)
  > With respect to the modalities... we have upgraded ourselves from being a lab-scale facility in some of these modalities to commercial-scale facilities. So ADCs... we have now commissioned the new Anthem commercial-scale facility. Peptides also, we have commissioned the commercial-scale facility.
- **[TREND] Global Biologics Patent Cliff** (POSITIVE, Change: EXPANDING): Anthem is expanding its technical moat into the high-growth GLP-1 (Semaglutide) space, leveraging full backward integration in fermentation which competitors lack. (1 expanding)
  > Anthem will arguably have one of the strongest positions in this space, because we are fully integrated all the way backward... Anthem has developed the technology to make the fermentation fragment as well.
- The Specialty Ingredients segment continues to grow at a healthy pace (19.7% YoY), though its share of total revenue has slightly decreased due to the explosive growth in CRDMO. (5 expanding across 1 engine) (POSITIVE, Change: EXPANDING)
  > Specialty ingredients delivered Rs. 98 crores, a growth of 8% YoY... Specialty ingredients contributed 17% to our revenue.

### Future Growth

- **[METRIC] CDMO Order Book Growth** (NEGATIVE, Trend: DECELERATING): The CRDMO business is showing strong acceleration, delivering INR 452.7 crores in Q1 FY26, which management notes is a ramp-up from the momentum started in Q2 FY25. (3 accelerating, 1 decelerating, 1 steady across 5 signals)
  > The CRDMO business delivered Rs. 513 crores revenues with a growth of 31% YoY basis.
- **[METRIC] Biologics COGS per Gram** (POSITIVE, Trend: ACCELERATING): Margins are showing structural improvement and are accelerating due to complete backward integration and the discontinuation of expensive Chinese intermediate supplies. (2 accelerating across 2 signals)
  > The backward integration had helped us in terms of improving our material margins, which has moved up over Q3 and Q4 of last year.
- **[METRIC] Regulatory Filing Success Rate** (POSITIVE, Trend: STEADY): The pipeline is maturing rapidly; while late-phase molecules decreased from 10 to 6, this is because 4 successfully transitioned to commercial status, indicating a healthy conversion rate. (1 steady across 1 signal)
  > The 10 late phase has gone down to 6, because 4 of them have moved to commercial now.
- **[METRIC] Biosimilar Pipeline Risk-Adjusted NPV** (POSITIVE, Trend: STEADY): The Phase 3 pipeline is steady with 6 molecules remaining after 4 successfully transitioned to commercial status. The early-stage pipeline remains robust with 130-140 molecules. (1 steady across 1 signal)
  > 4 molecules went commercial. So, still at 6... the pipeline on early stage is still robust.
- **[METRIC] R&D Spend as Percentage of Revenue** (NEUTRAL, Trend: STEADY): Margins remain healthy but have stabilized at a lower level (38%) compared to previous full-year peaks, though management expects them to remain steady in this 'zip code'. (1 steady across 1 signal)
  > The EBITDA was INR214.3 crores with the margins, EBITDA margins at 38%.
- **[PRINCIPLE] Biologics Manufacturing Scale** (POSITIVE, Trend: ACCELERATING): Expansion is accelerating with the recent commissioning of the CP7 block in Unit-2 and ongoing civil work for the massive Unit-4 facility, which is expected to see major capital outflow by March 2027. (1 accelerating, 1 new trend, 3 steady across 5 signals, 2 leading indicators)
  > In Phase 1 of that expansion, and we are looking at investing almost about Rs. 1,200 odd crores across two years... This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation vis-à-vis our current capacity which is 425 kiloliters custom synthesis and 
- **[PRINCIPLE] Biosimilar Pipeline Depth** (POSITIVE, Trend: STEADY): The pipeline is successfully maturing as molecules move from Phase 3 to commercial status. The commercial portfolio increased from 10 to 12 molecules this quarter. (1 steady, 1 new trend across 2 signals, 1 leading indicator)
  > now the late-stage pipeline stands at 10 Phase 3 molecules. Along with that, we work on 100 plus programs on the early-stage side.
- **[PRINCIPLE] CDMO Revenue Diversifies Risk** (POSITIVE, Trend: ACCELERATING): The number of commercial molecules has increased from 10 at the time of IPO to 14 currently, representing a 40% growth in the commercial portfolio. (3 accelerating, 2 steady across 5 signals)
  > the current contribution from these four molecules will be in the range of closer to about 8% to 9% of our revenues... It takes two to three years to build to have the ramp-up.
- **[PRINCIPLE] Global Partnerships Validate Quality** (POSITIVE, Trend: NEW_TREND): The company is deepening its engagement with global giants, confirming major ongoing engagements with two 'really major' global pharma companies expected to yield results in the near term. (3 new trend across 3 signals)
  > However, last year we've had two direct contacts and two direct relationships, which are now, I'm glad to say, growing healthily.
- **[TREND] Contract Biologics Manufacturing Growth** (POSITIVE, Trend: ACCELERATING): Capacity expansion is accelerating with the commissioning of 54 KL at Unit II and the phased commencement of Unit III, including specialized peptide and hi-potent facilities. Construction on the 30-acre Unit IV greenfield site has also begun. (1 accelerating, 1 steady across 2 signals, 1 leading indicator)
  > we do a variety of payloads, at least I think 15 - 20 payloads we work on... that's a very interesting area and we have a huge amount of activity going on there.
- **[TREND] Global Biologics Patent Cliff** (POSITIVE, Trend: NEW_TREND): The contribution from new commercial molecules is in an early ramp-up phase. While currently small, management estimates the peak market potential for these four molecules at $10 billion. (1 new trend across 1 signal)
  > Now we are in conversations with I would say all the big players to give them an alternate, which is based here in India. We're in a very good position as far as GLP-1 goes... That could happen in six months, it could happen in eight months.
- EBITDA margins are showing an accelerating trend, reaching 44.5% in the most recent quarter, up significantly from 40.4% a year ago and 38.1% in the preceding quarter. (4 accelerating, 1 decelerating across 5 signals, 1 leading indicator) (POSITIVE, Trend: ACCELERATING)
  > Net Cash (₹ Mn) 12,312 (Dec 31, 2025) 13,743 (Mar 31, 2026)

### Risk Assessment

- **[METRIC] CDMO Order Book Growth** (POSITIVE): Concentration risk is slightly intensifying as CRDMO revenue grew 70.5% YoY, now accounting for 83.8% of total revenue compared to 83.9% in the previous quarter, maintaining a heavy reliance on this single segment. (2 intensifying, 3 easing)
  > Q1FY26 Revenue Split: CRDMO 83.8%, Specialty Ingredients 16.2%
- **[METRIC] Biologics COGS per Gram** (POSITIVE): Margins are actually improving and showing structural resilience due to successful backward integration and the discontinuation of expensive Chinese intermediate supplies. (3 easing)
  > What had happened over the course of this financial year is, we have completely discontinued China supplies because now we manufacture the intermediate in-house... so we are completely backward integrated.
- **[PRINCIPLE] Biologics Manufacturing Scale** (NEGATIVE, Risk: HIGH): The company's net cash position has significantly improved to ₹9,934 Mn as of Sept 30, 2025, up from ₹7,848 Mn in the previous quarter, providing a larger buffer for upcoming capital expenditures. (1 easing, 4 stable, 2 high-severity)
  > In Phase 1 of that expansion, and we are looking at investing almost about Rs. 1,200 odd crores across two years, this year FY27 and in FY28. We aim to complete the Phase 1 expansion by March '28 financial year... Unit 4 is going to be much larger than all the units put together.
- **[PRINCIPLE] Biosimilar Pipeline Depth** (NEUTRAL): Concentration remains high with CRDMO contributing Rs. 926 Cr (85%) of the Rs. 1,090 Cr H1 revenue, though the company is aggressively pursuing new high-growth areas like GLP-1 and Biosimilars. (1 stable)
  > Our CRDMO business out of that has delivered Rs. 926 Cr of revenue and our specialty ingredients has delivered Rs. 163 Cr in revenue.
- **[PRINCIPLE] CDMO Revenue Diversifies Risk** (NEUTRAL, Risk: MODERATE): Specialty Ingredients revenue declined 13.1% YoY and 10.7% QoQ, confirming the volatility and potential crowding out by the dominant CRDMO segment. (2 intensifying, 2 easing, 1 stable)
  > Q4FY26 Revenue Split: CRDMO 83.9%
- **[TREND] Contract Biologics Manufacturing Growth** (POSITIVE, Risk: MODERATE): The risk is stable; management acknowledges the need to compete with China, particularly in the emerging GLP-1 space where they aim to be a leading producer. (2 stable, 1 resolved)
  > In Korea particularly and in China also, the large companies have built up massive capacities. In that sense, they are ahead of us. There's no denying that. Because there is the upfront investment in large molecules is quite large, so you must be willing to invest billions of dollars for those kinds
- The risk is intensifying due to increased political rhetoric regarding drug pricing and potential US tariffs, though management believes their European supply route provides a buffer. (5 intensifying) (NEGATIVE, Risk: MODERATE)
  > the net expense recognized in "Exceptional Item" amounts to Rs. 243.91 million in the Consolidated financial results... arising due to change in wage definition and gratuity provisions.

### Scenario Analysis

- An Iran conflict would trigger a Rupee depreciation as India's current account deficit widens due to oil shocks, which directly boosts Anthem's 'Other Income' through forex gains on its massive export book. Although rising crude prices inflate raw material and fermentation costs, the company's high gross margins (65%+) and successful elimination of Chinese intermediate dependencies allow it to absorb these shocks better than peers. Ultimately, the conflict accelerates the structural shift toward domestic manufacturing, where Anthem’s Unit 4 expansion positions it as a critical alternative to global supply chain disruptions. (POSITIVE)
  > Nobody anticipated a war in in the Middle East. There's so many so many things, which are up in the air... But these are times where there are inflationary pressures, that we can see it.
- The deployment of AI for molecular design by global pharma firms (First Order) accelerates the volume of viable drug candidates, which directly increases the demand for Anthem’s high-tech fermentation and custom synthesis capacity (Second Order). As AI shortens the discovery phase, the bottleneck shifts to specialized manufacturing, allowing Anthem to capture higher margins through its 'science-led' platform and backward integration. Ultimately, this shifts the company's leadership position toward being a critical physical-world enabler for AI-driven biotech, decoupling its growth from traditional labor-intensive R&D cycles. (POSITIVE)
  > Yes. AI is coming into all, kinds of function of the company. It starts with the recruitment, with HR, with warehousing. So, we are trying to bring in.

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for Indian equities.*